low environmental impact processing
At all stages of design, development and manufacture, we have given priority to our vision of environmental friendliness, offering a technology :
Clean and durable
The technology of production and the treatment delivery methods do not impact the environment of the patient, since it is manufactured autologously from its sample. Similarly, the nature of the therapeutic vaccine (composed of hydroxyapatite and the proteins of its tumour cells) does not lead to any risk of the creation and release of pharmaceutical residues.
Simple and suitable
The manufacture and use of the treatment are adapted and applicable to a simple regulated pharmaceutical environment of the GMP type. This is completely independent of bio-production and cell culture techniques, without logistical constraints and without the need to contribute multiple hospital services inherent in other targeted therapies.
Accessible and cost-effective
In an economic context predicting an increase in health expenditure linked to the increasingly increased marketing of specific immunotherapies in the treatment of cancers, HASTIM's proposed treatment is simple to apply and provides an economic and environmentally-friendly solution.